A trial fibrillation (AF) is the most common cardiac arrhythmia, and those afflicted have reduced quality of life, functional status, and cardiac performance.[@b1] Patients with AF have a higher risk of stroke, heart failure, and premature death relative to patients without AF.[@b2] It is estimated that 2.5% of the population worldwide has AF, and the prevalence of AF increases substantially with age, especially after 50 years of age.[@b3] AF is more common among white persons than black persons, and men are at 1.5 times greater risk for developing AF than women.[@b3],[@b4] In the United States, about 2.3 million people currently have AF, and the numbers are increasing rapidly. It is predicted that by 2050, 5.6 million people in the United States will have AF, with more than half of those patients aged \>80 years.[@b3] This represents a 2.5-fold increase over 50 years, reflecting both the growing proportion of elderly persons in the population[@b3] and the increasing rates of comorbidities associated with AF, including coronary artery disease, hypertension, and congestive heart failure.[@b2]

Although the prevalence of AF is increasing, cognitive disorders are also on the rise in tandem with the aging of the population. Patients with mild cognitive impairment have increased morbidity and lower quality of life relative to patients with normal cognitive function,[@b5],[@b6] and compared with those with normal cognition, patients with dementia have increased mortality.[@b7] The diagnosis of mild cognitive impairment is made based on cognitive testing scores that are lower than expected for a patient's age, typically due to memory, but these persons maintain independent functional status in terms of activities of daily living and instrumental activities of daily living.[@b8] Patients are diagnosed with dementia when they have evidence of cognitive impairment on testing and this cognitive deficit affects their functional status.[@b9]

More than 20% of people aged \>70 years have mild cognitive impairment.[@b10] There are ≈800 000 cases of mild cognitive impairment and ≈560 000 cases of dementia annually in the United States, and patients who have progressed from mild cognitive impairment to dementia account for 75% of patients with dementia.[@b11] The prevalence of dementia increases with age from about 5% of patients in their 70s to nearly 40% of patients in their 90s.[@b12] The aging population is predicted to result in an increase in the prevalence of dementia such that \>80 million people worldwide are expected to have dementia by 2040.[@b13],[@b14] Historically, patients were classified as having Alzheimer's disease if they had neurodegenerative disease and vascular dementia or if they had cerebral vascular lesions. This was an oversimplification because most patients have a combination of neurodegenerative and vascular lesions contributing to the clinical phenotype of dementia.[@b15]

This review is intended to review the literature and present the current findings on the association between AF and cognitive decline. The focus is on whether evidence shows that AF is associated with cognitive impairment beyond the relationship with stroke.

Literature Search Methods
=========================

Series of PubMed literature searches were conducted. The searches were limited to articles written in English and were performed January 7, 2015. The search terms included *atrial fibrillation* and *hypoperfusion*, *atrial fibrillation* and *cognitive function*, *atrial fibrillation* and *silent stroke*, *atrial fibrillation* and *covert stroke*, *atrial fibrillation* and *cognitive impairment*, *atrial fibrillation* and *dementia*, *cardiovascular* and *dementia*, and *cognitive decline*. The search yielded 3279 unique articles, and the titles and abstracts were screened for relevance. The citations in all relevant articles were examined for additional studies. The principal findings from the search follow, presented by topic.

Cardiovascular Disease and Cognitive Impairment
-----------------------------------------------

The link between cardiovascular diseases and cognitive impairment has been well established. Coronary artery disease was associated with cognitive decline in a 6-year longitudinal study,[@b16] and elevated risk scores for coronary heart disease, such as the Framingham Risk Score, were associated with cognitive decline in adults aged \>50 years in both primarily white and primarily Hispanic populations.[@b17],[@b18] Blood pressure has been associated with cognitive decline, and this relationship includes hypertension, large variations in systolic blood pressure, and hypotension due to low cardiac output.[@b19] A meta-analysis of 2937 heart failure patients and 14 848 control patients found that heart failure was associated with cognitive impairment (hazard ratio \[HR\] 1.62, 95% CI 1.48 to 1.79).[@b20]

Cognitive Decline and Stroke
----------------------------

Stroke is a major cause of cognitive impairment,[@b21],[@b22] and even mild to moderate strokes cause long-term decline in cognitive function.[@b23] A study by Tatemichi et al was designed to determine the association between stroke and cognitive domains (memory, orientation, verbal skills, visuospatial ability, abstract reasoning, and attention to detail) affected by stroke. The study evaluated 227 patients 3 months after stroke and 240 control patients with no history of stroke. Impairment of memory, orientation, language, and attention were associated with stroke.[@b24] Among a group of patients with cerebral small vessel disease, the number of lacunar infarcts at baseline was associated with cognitive impairment 3 to 5 years after presentation (HR 3.06, 95% CI 1.71 to 5.50).[@b25]

White Matter Lesions and Silent or Covert Cerebral Infarcts
-----------------------------------------------------------

The mechanisms mediating cognitive disorder in cardiovascular diseases, including hypertension and atherosclerosis, are not entirely clear but appear to be related to central nervous system changes, including overt stroke events and covert cerebral infarcts.[@b26]--[@b29] These covert cerebral infarcts are non-clinical events that are detected by magnetic resonance imaging of the brain, such as silent cerebral infarcts and white matter lesions.[@b30] White matter lesions originate from demyelination, gliosis, cerebral infarct, and small vessel disease.[@b31]--[@b33] White matter lesions on magnetic resonance imaging have been associated with cognitive decline,[@b34] especially speed of cognitive processes.[@b35] A meta-analysis showed that white matter lesions were associated with stroke (HR 3.3, 95% CI 2.6 to 4.4), dementia (HR 1.9, 95% CI 1.3 to 2.8), and death (HR 2.0, 95% CI 1.6 to 2.7).[@b36] Furthermore, cardiovascular risk conditions of hypertension (odds ratio 1.73, 95% CI 1.23 to 2.42) and diabetes mellitus (odds ratio 3.68, 95% CI 1.89 to 7.19) have also been associated with covert or silent cerebral infarcts.[@b37] Silent or covert cerebral infarcts appear meaningful, being associated with cognitive decline, increased risk of stroke, and dementia.[@b38]--[@b41] The Rotterdam Scan Study of 1015 persons identified an HR of 2.26 (95% CI 1.09 to 4.70) for the association between silent cerebral infarcts and dementia.[@b42] Similarly, data from the Atherosclerosis Risk in Communities study found that incident AF was associated with cognitive decline in patients with silent cerebral infarcts diagnosed by magnetic resonance imaging.[@b43]

Atrial Fibrillation and Risk of Embolic Events
----------------------------------------------

The extent to which AF is related to cognitive impairment is unclear. Although AF is associated with many cardiovascular conditions, it is also an established risk factor for ischemic stroke and systemic thromboembolism.[@b22],[@b44],[@b45] AF is associated with an ≈3- to 5-fold increase in the risk of stroke.[@b4],[@b46] Stroke risk in AF patients increased with age, and up to 30% of strokes were in people aged \>80 years.[@b47],[@b48] Among patients with coronary heart disease or heart failure, AF was associated with a 2-fold increase in stroke risk for men and a 3-fold increase for women.[@b46] Strokes secondary to AF had worse prognoses than strokes in patients without AF.[@b46],[@b49]

Overview of Anticoagulation for Atrial Fibrillation
---------------------------------------------------

Risk stratification and stroke prevention are critical to the management of AF patients, and the current European and US guidelines for the management of AF are similar in their recommendations.[@b1],[@b50] Oral anticoagulation is important in patients at high risk for stroke because it decreases the stroke rate by nearly 80%,[@b51] and patients at the highest risk for stroke derive the most benefit.[@b47],[@b52] One of the most commonly used anticoagulants is adjusted-dose warfarin, which reduces stroke risk by 64% relative to aspirin.[@b53] Relative to aspirin, warfarin approximately doubles the risk of intracranial and major extracranial hemorrhage, but the absolute rate of intracranial hemorrhage with warfarin is low at 0.2% to 0.4% per year.[@b53],[@b54]

A number of targeted non-vitamin K antagonist oral anticoagulants are now approved by the US Food and Drug Administration for stroke prevention in nonvalvular AF, including dabigatran (direct thrombin inhibitor), rivaroxaban (factor Xa inhibitor), apixaban (factor Xa inhibitor), and edoxaban (factor Xa inhibitor) (Table[1](#tbl1){ref-type="table"}).[@b55]--[@b58] The most important benefits that these newer drugs offer over warfarin are a \>50% reduction in intracranial bleeding and a 10% reduction in all-cause mortality.[@b54] In fact, the novel oral anticoagulants appear to have similar risk profiles to low-dose aspirin in terms of major bleeding and intracranial hemorrhage.[@b59]

###### 

Comparative Effectiveness Trials of Non--Vitamin K Oral Anticoagulants Versus Warfarin

                                             Apixaban (ARISTOTLE)   Dabigatran Low-Dose (RE-LY)   Dabigatran High-Dose (RE-LY)   Rivaroxaban (ROCKET)   Edoxaban Low-Dose (ENGAGE)   Edoxaban High-Dose (ENGAGE)
  ------------------------------------------ ---------------------- ----------------------------- ------------------------------ ---------------------- ---------------------------- -----------------------------
  Number of patients                         18 201                 18 113                        14 264                         21 105                                              
  Mean CHADS2 score                          2.1±1.1                2.1±1.1                       2.2±1.2                        3.5±0.9                2.8±1.0                      2.8±1.0
  Medication dose                            5 mg BID               110 mg BID                    150 mg BID                     20 mg daily            30 mg daily                  60 mg daily
  Stroke or systemic embolism, HR (95% CI)   0.79 (0.66 to 0.95)    0.91 (0.74 to 1.11)           0.66 (0.53 to 0.82)            0.79 (0.66 to 0.96)    1.07 (0.87 to 1.31)          0.79 (0.63 to 0.99)
  Ischemic stroke, HR (95% CI)               0.92 (0.74 to 1.13)    1.11 (0.89 to 1.40)           0.76 (0.60 to 0.98)            0.91 (0.73 to 1.13)    1.41 (1.19 to 1.67)          1.00 (0.83 to 1.19)
  Total mortality, HR (95% CI)               0.89 (0.80 to 0.998)   0.91 (0.80 to 1.03)           0.88 (0.77 to 1.00)            0.85 (0.70 to 1.02)    0.87 (0.79 to 0.96)          0.92 (0.83 to 1.01)
  Intracranial hemorrhage, HR (95% CI)       0.42 (0.30 to 0.58)    0.31 (0.20 to 0.47)           0.40 (0.27 to 0.60)            0.67 (0.47 to 0.93)    0.30 (0.21 to 0.43)          0.47 (0.34 to 0.63)
  Major bleeding, HR (95% CI)                0.69 (0.60 to 0.80)    0.80 (0.69 to 0.93)           0.93 (0.81 to 1.07)            1.04 (0.95 to 1.13)    0.47 (0.41 to 0.55)          0.80 (0.71 to 0.91)

HR indicates hazard ratio.

Beyond Stroke: Atrial Fibrillation and Cognitive Decline
========================================================

The role of AF in cognitive decline, independent of stroke, is uncertain. Many studies have found that AF is associated with cognitive decline,[@b40],[@b44],[@b60],[@b61] but it is less clear whether this association is directly related to AF itself or is a function of the population in which AF occurs, that is, an aging cohort with multiple comorbidities (Table[2](#tbl2){ref-type="table"}).[@b22],[@b41],[@b43],[@b44],[@b60],[@b62]--[@b83] Cognitive impairment has been identified in as many as 69% of AF patients.[@b84] In 1 study, AF was associated with increased risk of cognitive decline, new dementia, loss of independence in everyday life, and admission to long-term care facilities.[@b22] Conversely, others have found no differences in cognitive decline between AF and non-AF patients.[@b44]

###### 

Data on Cognitive Decline in Atrial Fibrillation

  Author                Year   Patients   AF Patients   Population                       Follow-up           Cognitive Function Assessment                                               AF Association Cognitive Decline
  --------------------- ------ ---------- ------------- -------------------------------- ------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------------------------
  Farina[@b62]          1997   74         37            21 PAF, 16 persistent AF         Cross-section       MMSE[\*](#tf2-2){ref-type="table-fn"}                                       Statistically significant for persistent, not significant for paroxysmal
  Ott[@b63]             1997   6584       195           Mean age 69±9 years              Cross-section       MMSE and Geriatric Mental State Schedule                                    Adjusted OR 1.7 (1. 2 to 2.5)
  Kilander[@b64]        1998   952        44            Mean age 72±1 years              Cross-section       Trail Making Tests A and B, MMSE                                            Unadjusted, statistically significant
  O'Connell[@b65]       1998   81         27            Mean age 72±1 years              Cross-section       Mini-Mental Status[†](#tf2-3){ref-type="table-fn"}                          MMSE not statistically significant
  Rozzini[@b66]         1999   269        55            13 PAF, 42 persistent AF         Cross-section       MMSE                                                                        Adjusted OR for paroxysmal AF 1.2 (0.3 to 4.8), OR for persistent AF 3.2 (1.5 to 6.6)
  Elias[@b67]           2006   1011       59            Men, mean age 61 years           Cross-section       Wechsler Adult Intelligence Scale[‡](#tf2-4){ref-type="table-fn"}           Adjusted, statistically significant
  Jozwiak[@b68]         2006   2314       547           Median age 80 years (75 to 86)   Cross-section       MMSE                                                                        OR 1.56 (1.27 to 1.92, *P* =0.0001)
  Debette[@b69]         2007   83         32            Mean age 62 years                Cross-section       MMSE                                                                        Adjusted OR 8.1 (1.9 to 34.6, *P* =0.008)
  Rastas[@b70]          2007   553        122           85 years and older               Cross-section       MMSE[§](#tf2-5){ref-type="table-fn"}                                        Unadjusted, not statistically significant
  Knecht[@b60]          2008   533        87            Mean age 63±8 years              Cross-section       Composite[\|\|](#tf2-6){ref-type="table-fn"}                                Adjusted, statistically significant
  Bilato[@b71]          2009   1576       135           Mean age 74 years                Cross-section       MMSE                                                                        Adjusted OR 1.14 (0.73 to 1.80)
  Bellomo[@b72]         2012   57         26            Mean age 72±8 years              Cross-section       MMSE                                                                        Adjusted, statistically significant
  Gaita[@b73]           2013   270        180           61% with CHA~2~-DS~2~-VaSc \<2   Cross-section       Repeatable Battery for the Assessment of Neuropsychological Status          Unadjusted, statistically significant
  Stefansdottir[@b41]   2013   4251       330           Mean age 76±5 years              Cross-section       Modified California Verbal Learning Test                                    Adjusted, statistically significant
  Horstmann[@b74]       2014   788        165           Mean age 67±14 years             Cross-section       Informant questionnaire on cognitive decline in the elderly                 OR of 2.97 (1.0 to 8.8, *P* =0.05)
  Tilvis[@b75]          2004   650                                                       Mean 5 years        MMSE and Clinical Dementia Rating                                           RR 2.8
  Forti[@b76]           2006   431        13            Mean age 75±5 years              Mean of 4 years     MMSE                                                                        Adjusted HR 1.10 (0.40 to 3.03)
  Park[@b44]            2007   362        174           Mean age 76 years                Mean 3 years        MMSE                                                                        No significant association
  Peters[@b77]          2009   3336       190           Mean age 53±6 years              Mean of 2 years     MMSE                                                                        HR 1.031 (0.619 to 1.718)
  Bunch[@b78]           2010   37 025     10 161        Mean age 61±18 years             Mean of 5 years     ICD-9 code for dementia                                                     Adjusted OR 1.73 (*P* =0.001)
  Dublin[@b79]          2011   3045       402           Median age 74 years              Mean of 7 years     Cognitive Abilities Screening Instrument                                    Adjusted HR 1.50 (1.16 to 1.94)
  Li[@b80]              2011   650        30            Mean age 67 years                Mean of 5 years     MMSE                                                                        Adjusted OR 1.09 (0.54 to 2.20, *P* =0.82)
  Marengoni[@b81]       2011   785        68            Mean age 78 years                Mean of 4 years     MMSE                                                                        Adjusted HR 0.8 (0.4 to 1.5)
  Marzona[@b22]         2012   31 546     3068          Mean age 67±7 years              Median 56 months    MMSE                                                                        HR 1.30 (1.14 to 1.49)
  Haring[@b82]          2013   6455       255           Women age 60 to 84 years         Mean of 8 years     Annual modified MMSE                                                        HR 1.25 (0.78 to 2.0)
  Thacker[@b83]         2013   5150       552           Mean age 73±5 years              Mean of 7 years     Annual modified MMSE                                                        Adjusted, statistically significant
  Chen[@b43]            2014   935        48            Mean age 62±4 years              Median 10.6 years   Delayed word recall, digit symbol substitution, first-letter word fluency   Statistically significant

AF indicates atrial fibrillation; HR, hazard ratio; ICD-9, International Classification of Diseases, 9th Revision; MMSE, Mini Mental Status Exam; OR, odds ratio; PAF, paroxysmal atrial fibrillation; RR, relative risk. Data are displayed as median (interquartile range), mean +/− standard devision, OR (95% confidence interval), and HR (95% confidence interval).

Also includes Weschsler Adult Intelligence, Logical Memory Test, Paired Associated Learning Test, Corsi's Block Tapping Test, Attentional Matrices, Raven Progressive Matrices, Judgment of Line Orientation, Rey-Osterrieth Complex, Verbal Fluency for Letters, Wisconsin Sorting Card Test.

Also includes National Adult Reading Test, Wechsler Logical Memory Test, Rey Complex Figure Test, Digit Span, Paced Auditory Serial Addition Test.

Also includes Wechsler Memory Scale, Hooper Visual Organization Test, Halstead-Reitan Battery.

Also includes Short Portable Mental Status Questionnaire, Clinical Dementia Rating.

Auditory verbal learning test, Stroop test, Trail-making test, Wechsler Memory Scale, category and letter fluency, Rey-Osterrieth complex figure test, digit symbol substitution test.

Multiple potential mechanisms explain the association between AF and cognitive decline. Cerebral microbleeds increase with age and anticoagulation,[@b85] and microbleeds are associated with cognitive decline.[@b86] Cerebral hypoperfusion during AF may contribute to cognitive impairment. Decreased diastolic cerebral perfusion has also been associated with AF,[@b87] and irregularity of ventricular contraction during AF affects preload and cardiac output, which may result in a decreased mean cerebral flow.[@b88] Inflammatory markers, including C-reactive protein, TNF-α, and IL-6, are associated with AF.[@b89]--[@b91] Inflammatory markers such as C-reactive protein and IL-6 have been associated with cognitive decline and Alzheimer's disease.[@b92],[@b93]

Given the propensity to form thrombus (micro- and macrothrombi) in the left atrium and atrial appendage in the setting of AF, it is biologically plausible that AF could contribute to cognitive impairment through chronic ischemic--embolic insults, even without overt evidence of clinical stroke. Cognitive dysfunction in AF patients has been correlated with less effective anticoagulation, more vascular events, and more bleeding, likely related to decreased adherence to prescribed oral anticoagulation.[@b45] In support of the hypothesis of chronic subclinical embolic contribution to cognitive decline in AF, silent infarcts are significantly more frequent among patients with AF than in those without AF (Table[3](#tbl3){ref-type="table"}).[@b39],[@b41],[@b43],[@b73],[@b94]--[@b97] The prevalence of silent cerebral infarcts among patients with AF varies widely in the literature but has been reported to be as high as 92%, which is twice the prevalence of silent cerebral infarcts among patients with normal sinus rhythm.[@b39],[@b73] Of the 92% of patients with silent cerebral infarcts, 61% had CHA~2~DS~2~-VASc scores ≤1, meaning they were not currently recommended to be treated with oral anticoagulation based on the AF guidelines in the United States.[@b73] Furthermore, cognitive impairment rates are higher among AF patients than non-AF patients, even after excluding all patients with abnormalities on magnetic resonance imaging of the brain.[@b60]

###### 

Data on Silent Cerebral Infarct in Atrial Fibrillation

  Author                Year   Patients   Population           Design                                                    Silent Cerebral Infarcts
  --------------------- ------ ---------- -------------------- --------------------------------------------------------- ------------------------------------------------------------------
  Petersen[@b96]        1987   58         29 (50%) with AF     AF patients matched to non-AF patients, single CT head    48% of AF patients and 28% of non-AF patients (*P*\>0.10)
  Kempster[@b97]        1988   222        54 (24%) with AF     Retrospective analysis of patients with CT head           13% of AF patients and 4% of non-AF patients (*P*\<0.05)
  Raiha[@b95]           1993   204        30 (15%) with AF     CT head scans from a geriatrics clinic                    73% of AF patients and 48% of non-AF patients (*P* =0.0095)
  Ezekowitz[@b39]       1995   516        516 (100%) with AF   Noncontrast CT head done at beginning and end of study    15% of AF patients
  de Leeuw[@b94]        2000   1077       28 (3%) with AF                                                                RR of white matter lesions 2.2 (95% CI 1.0, 5.2)
  Gaita[@b73]           2013   270        180 (67%) with AF    90 sinus rhythm, 90 paroxysmal AF, and 90 persistent AF   89% of paroxysmal AF, 92% of persistent AF, and 46% sinus rhythm
  Stefansdottir[@b41]   2013   4251       330 (8%) with AF     Single MRI brain                                          49% of AF patients and 29% of non-AF patients (*P*\<0.001)
  Chen[@b43]            2014   935        48 (5%) with AF      Serial MRI scan at baseline and 9 to 13 years later       33% of AF patients and 17% of non-AF patients

AF indicates atrial fibrillation; CT, computed tomography; MRI, magnetic resonance imaging; RR, relative risk.

Among AF patients with neurological imaging, the number of abnormal brain areas with tissue loss was significantly greater compared with non-AF patients.[@b22],[@b96] The areas with tissue loss were usually located in the cortex, but there was no difference in the size of the lesions between control and AF patients.[@b96] Silent cerebral infarction was not a predictor of stroke in AF patients.[@b39] AF has also been associated with smaller brain volumes than in patients without AF, and AF has been associated with lower total brain mass, gray matter, and white matter.[@b41] The longer AF was present, the more brain volume decreased, and this was noted even without overt cerebral infarction. The memory domain appeared disproportionately affected to a greater degree.[@b41] Because silent infarct risk in AF patients is likely underestimated, many patients may not be receiving optimal anticoagulation treatment.[@b98]

Evaluating Cognitive Decline in Atrial Fibrillation
===================================================

There is no single, universally accepted test to assess cognitive function. The Alzheimer's Association provided 16 cognitive function tools that were evaluated in several review articles and that could be used by primary care providers to assess cognitive impairment (Table[4](#tbl4){ref-type="table"}).[@b99] One of the most commonly reported cognitive function tests in the research literature is the Mini Mental Status Examination (MMSE), which has been in use since 1975 to detect memory loss and to assess cognitive function. Typically, scores \<24 are suggestive of dementia, and scores of 24 or 25 are associated with increased risk for developing dementia within 3 years.[@b24] Poor performance on the MMSE in the first week after acute ischemic stroke is one of the important predictors of cognitive decline over the ensuing 3 months.[@b24] Many of the existing studies evaluating cognitive impairment in AF have used the MMSE to evaluate cognitive decline.[@b44],[@b100],[@b101] Among AF patients, low scores on the MMSE have been associated with out-of-range International Normalized Ratios and an increased risk of vascular events and bleeding in AF patients.[@b24]

###### 

Cognitive Function Tests That Could be Used to Screen for Cognitive Impairment

  ----------------------------------------------
  7-Minute Screener
  Abbreviated Mental Test
  Cambridge Cognitive Examination
  Clock Drawing Test
  General Practitioner Assessment of Cognition
  Mini-Cog
  Memory Impairment Screen
  Mini Mental State Examination
  Montreal Cognitive Assessment
  Rowland University Dementia Assessment
  Short and Sweet Screening Instrument
  Short Blessed Test
  St. Louis University Mental Status
  Short Portable Mental Status Questionnaire
  Short Test of Mental Status
  Time and Change Test
  ----------------------------------------------

There were concerns that the MMSE was less sensitive with mild cognitive impairment.[@b102],[@b103] The Montreal Cognitive Assessment (MoCA) was developed as a screening tool for early cognitive decline, and the MoCA was found to have a sensitivity of 90% in identifying mild cognitive impairment compared with a sensitivity of only 18% with the MMSE.[@b104] The MoCA was also more sensitive in detecting mild cognitive impairment than the Cognitive Capacity Screening Examination[@b105] (sensitivity 74%) and the DemTect[@b106] (sensitivity 80%), which were 2 other cognitive function screening tests.

Vascular cognitive impairment, as seen in AF patients with stroke and transient ischemic attack, was associated with deficits in executive function, attention, and speed of information processing more than other domains.[@b107] The MMSE places more emphasis on language and memory than on other cognitive domains. The MoCA weighs executive function and attention more heavily than the MMSE, and the MoCA has been shown to be superior to the MMSE in identifying cognitive impairment in patients with vascular disease due to TIA or stroke.[@b108]

Antithrombotics and Cognitive Decline in Atrial Fibrillation
============================================================

There is variation across the available data regarding the effects of antithrombotic therapy on cognitive function among patients with AF. In a nonrandomized study, warfarin therapy did not affect the association between brain volume loss and AF.[@b41] In another study, the use of antithrombotic agents did not affect cognitive decline among AF patients.[@b22] Similarly, Park and colleagues found no differences in cognitive decline among AF patients on aspirin, warfarin, or neither.[@b44] An observational study, however, found a trend toward an association between warfarin use and lower rates of cognitive decline among patients with AF.[@b109] The Birmingham Atrial Fibrillation Treatment of the Aged Study randomized 973 patients with CHA~2~DS~2~-VASc of at least 2 to warfarin versus aspirin and found a non--statistically significant trend toward decreased cognitive decline at 33 months within the warfarin group.[@b110] The clinical benefit of warfarin was seen only when a high frequency of time is in the therapeutic range.[@b111] Data from the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-W) found that among patients who had AF, who had a mean CHADS~2~ score of 2, and who were on warfarin, cognitive dysfunction was associated with lower time in the therapeutic range of anticoagulation, suggesting that maintaining therapeutic anticoagulation may decrease cognitive decline.[@b45] Because non--vitamin K oral anticoagulants mitigate the challenges of time in the therapeutic range, there has been speculation that they may be able to slow or reverse cognitive decline among AF patients.

Additional prospective work is needed to quantify cognitive function and rates of cognitive decline among AF patients compared with non-AF patients, especially by using more sensitive tools such as the MoCA. An ongoing clinical trial is the Aspirin in Reducing Events in the Elderly (ASPREE) study (ClinicalTrials.gov identifier NCT01038583), which is comparing aspirin and placebo for prevention of death, dementia, or disability in 19 000 patients. A neuroimaging substudy (ENVIS-ion) will evaluate the effect of aspirin on the development of white matter hyperintense lesions, and results are expected in 2018.[@b112] More data are also needed on the relationship between cognitive decline with AF and estimated vascular embolic risk, as well as how this may be affected by anticoagulation. These findings may be particularly important among subpopulations of AF patients for whom the US guidelines do not currently recommended anticoagulation therapy over aspirin or no antithrombotic therapy (CHA~2~DS~2~-VASc score of 0 or 1).

Conclusions
===========

Most studies suggest that AF is independently associated with cognitive decline, even among patients with no clinical history of stroke. Cognitive decline is associated with stroke and silent cerebral infarcts, and patients with AF have higher rates of silent cerebral infarcts than patients without AF. The impact of anticoagulation on silent cerebral infarcts remains unknown. Cognitive decline is an important public health concern, and clinical trials are needed to evaluate the effect of oral anticoagulation on cognitive decline in patients with AF.
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